Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy

Adv Healthc Mater. 2022 Jan;11(1):e2101428. doi: 10.1002/adhm.202101428. Epub 2021 Nov 10.

Abstract

The dense and heterogeneous physical network of the extracellular matrix (ECM) in tumors represents a formidable barrier that limits intratumor drug delivery and the therapeutic efficacy of many anticancer therapies. Here, the two major nanomedicine strategies to circumvent intratumor ECM barriers: regulating the physiochemical properties of nanomedicines and remodeling the components and structure of the ECM are summarized. Nanomedicines can be rationally regulated by optimizing physiochemical properties or designed with biomimetic features to promote ECM permeation capability. Meanwhile, they can also be designed to remodel the ECM by modulating signaling pathways or destroying the components and architecture of the ECM via chemical, biological, or physical treatments. These efforts produce profound improvements in intratumor drug delivery and anticancer efficacy. Moreover, to aid in their anticancer efficacy, feasible approaches for improving ECM-circumventing nanomedicines are proposed.

Keywords: cancer therapy; drug delivery; extracellular matrix; nanomedicine; tumor penetration.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Drug Delivery Systems
  • Extracellular Matrix
  • Humans
  • Nanomedicine
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents